概括
患有髓状瘤和环染色体 (MN和RC) 的患者的结局不佳. 目前的治疗方法,包括低甲基化剂,并没有显著改善这一组的整体存活率或无进展存活率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 环状染色体 (RC) 是髓状瘤 (MN) 中获得的结构异常.
- RC与遗传物质的收益/损失和潜在的劣质患者结果有关.
- 缺乏以前关于MN与RC治疗反应的数据.
研究的目的:
- 分析MN和RC患者的结局.
- 评估不同治疗选择在这个患者队列中的有效性.
主要方法:
- 对31名MN和RC患者的回顾性分析.
- 总生存期 (OS) 和无进展生存期 (PFS) 的比较基于接受的治疗:支持性护理,化疗,单独使用低甲基化剂 (HMA),或与venetoclax一起使用HMA.
主要成果:
- 超过60%的患者患有TP53突变或17p损失.
- 支持性护理与较短的中位 OS (mOS) 相关.
- 在细胞毒性化疗,HMA或HMA加venetoclax时,没有观察到mOS或PFS的显著改善.
结论:
- 患有MN和RC的患者表现出特别糟糕的预后.
- 目前的治疗策略在改善生存结果方面表现出有限的有效性.
- 对于MN与RC的有效治疗策略代表了一个未满足的临床需求.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


